Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery
A Pharmacodynamic Study of Metformin in Patients With Resectable Pancreatic Cancer
Status: Enrolling
Updated:  1/15/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery
A Pharmacodynamic Study of Metformin in Patients With Resectable Pancreatic Cancer
Status: Enrolling
Updated: 1/15/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery
A Pharmacodynamic Study of Metformin in Patients With Resectable Pancreatic Cancer
Status: Enrolling
Updated:  1/15/2015
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery
A Pharmacodynamic Study of Metformin in Patients With Resectable Pancreatic Cancer
Status: Enrolling
Updated: 1/15/2015
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers
Status: Enrolling
Updated:  1/23/2015
Harvard Medical School/Brigham & Women's Hospital
mi
from
Boston, MA
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers
Status: Enrolling
Updated: 1/23/2015
Harvard Medical School/Brigham & Women's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers
Status: Enrolling
Updated:  1/23/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers
Status: Enrolling
Updated: 1/23/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers
Status: Enrolling
Updated:  1/23/2015
University of Texas - MD Anderson
mi
from
Houston, TX
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers
Status: Enrolling
Updated: 1/23/2015
University of Texas - MD Anderson
mi
from
Houston, TX
Click here to add this to my saved trials
Thromboelastography During Surgery for Malignant Pleural Mesothelioma
Thromboelastography During Surgery for Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  1/28/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Thromboelastography During Surgery for Malignant Pleural Mesothelioma
Thromboelastography During Surgery for Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 1/28/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma
Status: Enrolling
Updated:  2/18/2015
Clinical Research Facility
mi
from
Boston, MA
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma
Status: Enrolling
Updated: 2/18/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma
Status: Enrolling
Updated:  2/18/2015
Clinical Research Facility
mi
from
Boston, MA
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma
Status: Enrolling
Updated: 2/18/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma
Status: Enrolling
Updated:  2/18/2015
Clinical Research Facility
mi
from
Houston, TX
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma
Status: Enrolling
Updated: 2/18/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
Status: Enrolling
Updated:  2/26/2015
GSK Investigational Site
mi
from
Goodyear, AZ
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
Status: Enrolling
Updated: 2/26/2015
GSK Investigational Site
mi
from
Goodyear, AZ
Click here to add this to my saved trials
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
Status: Enrolling
Updated:  2/26/2015
GSK Investigational Site
mi
from
Scottsdale, AZ
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
Status: Enrolling
Updated: 2/26/2015
GSK Investigational Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
Status: Enrolling
Updated:  2/26/2015
GSK Investigational Site
mi
from
Sarasota, FL
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
Status: Enrolling
Updated: 2/26/2015
GSK Investigational Site
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
Status: Enrolling
Updated:  2/26/2015
GSK Investigational Site
mi
from
Nashville, TN
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
Status: Enrolling
Updated: 2/26/2015
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation
Individually Optimized Contrast-Enhancement 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation
Status: Enrolling
Updated:  3/16/2015
Ummc Msgcc
mi
from
Baltimore, MD
4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation
Individually Optimized Contrast-Enhancement 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation
Status: Enrolling
Updated: 3/16/2015
Ummc Msgcc
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer
Percutaneous Cryoablation for the Palliation of Abdominal Pain Associated With Pancreatic Cancer
Status: Enrolling
Updated:  3/17/2015
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer
Percutaneous Cryoablation for the Palliation of Abdominal Pain Associated With Pancreatic Cancer
Status: Enrolling
Updated: 3/17/2015
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer
Percutaneous Cryoablation for the Palliation of Abdominal Pain Associated With Pancreatic Cancer
Status: Enrolling
Updated:  3/17/2015
The Research Foundation of State University New York
mi
from
Stony Brook, NY
Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer
Percutaneous Cryoablation for the Palliation of Abdominal Pain Associated With Pancreatic Cancer
Status: Enrolling
Updated: 3/17/2015
The Research Foundation of State University New York
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer
Percutaneous Cryoablation for the Palliation of Abdominal Pain Associated With Pancreatic Cancer
Status: Enrolling
Updated:  3/17/2015
University Hospitals
mi
from
Cleveland, OH
Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer
Percutaneous Cryoablation for the Palliation of Abdominal Pain Associated With Pancreatic Cancer
Status: Enrolling
Updated: 3/17/2015
University Hospitals
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer
A Pilot Clinical Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer by Molecular Imaging of VEGFR2
Status: Enrolling
Updated:  3/17/2015
Stanford University Medical Center
mi
from
Palo Alto, CA
A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer
A Pilot Clinical Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer by Molecular Imaging of VEGFR2
Status: Enrolling
Updated: 3/17/2015
Stanford University Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Birmingham, AL
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Scottsdale, AZ
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Decatur, IL
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Decatur, IL
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Indianapolis, IN
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Ashland, KY
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Ashland, KY
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Concord, MA
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Concord, MA
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
St Clair Shores, MI
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
St Clair Shores, MI
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Tupelo, MS
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Tupelo, MS
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Great Falls, MT
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Great Falls, MT
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Rochester, NY
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Burlington, NC
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Burlington, NC
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigator
mi
from
Flat Rock, NC
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigator
mi
from
Flat Rock, NC
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Canfield, OH
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Canfield, OH
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
Gabrail Cancer Center
mi
from
Canton, OH
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Portland, OR
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Portland, OR
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Lancaster, PA
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Lancaster, PA
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Spartanburg, SC
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Nashville, TN
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Round Rock, TX
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Round Rock, TX
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
LaJolla, CA
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
LaJolla, CA
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Long Beach, CA
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Miami, FL
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Orange City, FL
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Orange City, FL
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Tampa, FL
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Peoria, IL
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Peoria, IL
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Skokie, IL
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Skokie, IL
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Goshen, IN
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Goshen, IN
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Wilmington, NC
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Wilmington, NC
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Winston Salem, NC
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Winston Salem, NC
Click here to add this to my saved trials
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated:  3/18/2015
GTx Investigative Site
mi
from
Sandusky, OH
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy
Status: Enrolling
Updated: 3/18/2015
GTx Investigative Site
mi
from
Sandusky, OH
Click here to add this to my saved trials
Breast Cancer Margin Delineation Using Polarization Subtraction Imaging Technology
Breast Cancer Margin Delineation Using Polarization Subtraction Imaging Technology: An Ex-vivo Pilot Study of Real-time Breast Margin Imaging in Women Undergoing Breast Conservation Surgery for Early Stage Breast Cancer
Status: Enrolling
Updated:  3/30/2015
University of Wisconsin
mi
from
Madison, WI
Breast Cancer Margin Delineation Using Polarization Subtraction Imaging Technology
Breast Cancer Margin Delineation Using Polarization Subtraction Imaging Technology: An Ex-vivo Pilot Study of Real-time Breast Margin Imaging in Women Undergoing Breast Conservation Surgery for Early Stage Breast Cancer
Status: Enrolling
Updated: 3/30/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Status: Enrolling
Updated:  3/30/2015
Radiology Associates of Albuquerque (RAA)
mi
from
Albuquerque, NM
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Status: Enrolling
Updated: 3/30/2015
Radiology Associates of Albuquerque (RAA)
mi
from
Albuquerque, NM
Click here to add this to my saved trials